WALTHAM, Mass. & MAASTRICHT, The Netherlands--(BUSINESS WIRE)--BG Medicine Inc. (“BG Medicine”) and ACS Biomarker B.V. i.o. (“ACS Biomarker”) today announced that they have entered into an agreement granting BG Medicine rights to develop and commercialize a biomarker-based molecular diagnostic test as a prognostic indicator of congestive heart failure (CHF). ACS Biomarker, with technology exclusively licensed from the University of Maastricht and other parties, is being founded to develop and commercialize cardiovascular biomarkers discovered at the Cardiovascular Research Institute Maastricht (CARIM).
